This report aims to equip investors with the basic knowledge required to understand the risks of investing in cell and gene-based technologies through contextualised and empirical experience, valuable insight from a series of leading industry stakeholders, and market research and analysis. Building on deep understanding of the major risks in commercialising advanced therapies this report offers insightful and pragmatic guidance to maximising return on investments in advanced therapies.
